Acurx Pharmaceuticals, Inc. Net Fee Amt
Acurx Pharmaceuticals, Inc. (ACXP) had Net Fee Amt of $296.22 as of 2026-09-01, per its S-1 filed 2026-09-08.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-08
- 2026-09-01: Net Fee Amt $296.22.
- 2026-05-01: Net Fee Amt $460.33.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-01 | $296.22 S-1 · filed 2026-09-08 |
| 2026-05-01 | $460.33 S-1 · filed 2026-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |